[go: up one dir, main page]

AU1175497A - A class of oligonucleotides, therapeutically useful as antitumoural agents - Google Patents

A class of oligonucleotides, therapeutically useful as antitumoural agents

Info

Publication number
AU1175497A
AU1175497A AU11754/97A AU1175497A AU1175497A AU 1175497 A AU1175497 A AU 1175497A AU 11754/97 A AU11754/97 A AU 11754/97A AU 1175497 A AU1175497 A AU 1175497A AU 1175497 A AU1175497 A AU 1175497A
Authority
AU
Australia
Prior art keywords
oligonucleotides
class
therapeutically useful
antitumoural agents
antitumoural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11754/97A
Inventor
Franco Quadrifoglio
Bruna Scaggiante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saicom Srl
Original Assignee
Saicom Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saicom Srl filed Critical Saicom Srl
Publication of AU1175497A publication Critical patent/AU1175497A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU11754/97A 1995-12-04 1996-12-04 A class of oligonucleotides, therapeutically useful as antitumoural agents Abandoned AU1175497A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT95MI002539A IT1277025B1 (en) 1995-12-04 1995-12-04 CLASS OF PHOSPHODIESTERIC OLIGONUCLEOTIDES WITH CYTOTOXIC ACTIVITY PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE
ITMI95A2539 1995-12-04
PCT/EP1996/005388 WO1997020924A1 (en) 1995-12-04 1996-12-04 A class of oligonucleotides, therapeutically useful as antitumoural agents

Publications (1)

Publication Number Publication Date
AU1175497A true AU1175497A (en) 1997-06-27

Family

ID=11372654

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11754/97A Abandoned AU1175497A (en) 1995-12-04 1996-12-04 A class of oligonucleotides, therapeutically useful as antitumoural agents

Country Status (3)

Country Link
AU (1) AU1175497A (en)
IT (1) IT1277025B1 (en)
WO (1) WO1997020924A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
WO2001042449A2 (en) 1999-12-10 2001-06-14 Anticancer, Inc. Methods for introducing genes into mammalian subjects
CZ20022372A3 (en) 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Therapeutically usable synthetic oligonucleotides
US20020091095A1 (en) 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
MXPA03001812A (en) * 2000-08-29 2004-05-21 Bioniche Life Sciences Inc Modulation of fas and fasl expression.
CA2421409A1 (en) * 2000-09-08 2002-03-14 Aventis Pasteur Use of lipopeptides for immunotherapy of hiv-positive subjects
DE10230692A1 (en) * 2002-07-08 2004-02-12 Epigenomics Ag Methods and nucleic acids for the analysis of methylation patterns within the DD3 gene
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
AU2006231498B2 (en) * 2005-04-04 2011-01-27 Trustees Of Boston University Methods of protection from oxidative stress
KR20090128494A (en) 2007-03-24 2009-12-15 겐자임 코포레이션 Antisense Oligonucleotide Administration Complementary to Human Apolipoprotein shock
US9107933B2 (en) 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
KR101802540B1 (en) * 2009-09-25 2017-11-28 큐알엔에이, 인크. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
WO2011081884A1 (en) * 2009-12-14 2011-07-07 Massachusetts Institute Of Technology Systems and methods related to optical nanosensors including photoluminescent nanostructures
IT1405761B1 (en) * 2010-09-13 2014-01-24 Univ Degli Studi Trieste GT APTAMERIC OLIGONUCLEOTIDS AND THEIR USE AS ANTI-HUMAN AGENTS
CN103547271A (en) 2011-04-27 2014-01-29 Isis制药公司 Modulation of apolipoprotein CIII (APOCIII) expression
TWI876659B (en) * 2022-11-29 2025-03-11 法信諾生醫股份有限公司 Oligonucleotide therapeutics and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
WO1995026190A1 (en) * 1994-03-25 1995-10-05 Akira Kaji Novel anti-hiv drug
WO1996011010A1 (en) * 1994-10-07 1996-04-18 Pharmagenics, Inc. Bridged and unbridged quadruplex/duplex oligonucleotides
PL321711A1 (en) * 1995-02-09 1997-12-22 Icn Pharmaceuticals Methods of and compositions for controlling the cd28 expression

Also Published As

Publication number Publication date
ITMI952539A0 (en) 1995-12-04
IT1277025B1 (en) 1997-11-04
WO1997020924A1 (en) 1997-06-12
ITMI952539A1 (en) 1997-06-04

Similar Documents

Publication Publication Date Title
GB9520822D0 (en) Therapeutically active compounds
AU5441896A (en) Cooperative oligonucleotides
AU4098096A (en) 2,8-disubstituted quinazolinones
AU5048596A (en) Improved electrode
AU1175497A (en) A class of oligonucleotides, therapeutically useful as antitumoural agents
AU6104196A (en) Novel n-substituted-2-amino-3',4'-methylene-dioxypropiopheno nes
AU4329396A (en) Use of 3,4-diphenylchromans
AUPN396295A0 (en) Ironing aid
AU6250496A (en) Eyedrop applicator
AU1141595A (en) Space truss integrated-construction robot
AUPN221795A0 (en) Biofilter
ZA966554B (en) Therapeutically Active Compounds.
AU4866496A (en) Polysilicon polish for patterning improvement
AU4839196A (en) Polyazacycloalkane compounds
AU6780298A (en) Production of 1,3-diaminopentane by hydrogenation of 3-aminopentanenitrile
AU1217797A (en) New compounds
AU6221796A (en) Novel herbicides
AU6657596A (en) Trindene compounds
AU7177496A (en) Piperidinylethylamide derivatives as serotonergic agents
AU1093697A (en) Active bio-compounds
AU6418396A (en) Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-ox-4-aza-5alp ha-androst-1-ene-17beta-carboxamide
AU9177398A (en) Endothermic process
AU7372696A (en) Hand-held urinal
AUPO877497A0 (en) Improved process
AU696576B2 (en) 4-amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds